Viable leukocytes (WBC)

Viable leukocytes refer to the population of living white blood cells, which are the primary components of the immune system responsible for protecting the body against infectious diseases and foreign invaders (StatPearls, NBK560882). This heterogeneous group includes granulocytes, monocytes, and lymphocytes, each playing distinct roles in innate and adaptive immunity. In the context of drug development, viable leukocytes are typically viewed as a physiological compartment or a safety biomarker rather than a discrete molecular target. For instance, the depletion of viable leukocytes, known as leukopenia, is a critical dose-limiting toxicity for many cytotoxic chemotherapies (StatPearls, NBK563146). Conversely, the activation or recruitment of specific leukocyte subsets is a primary goal of many immunotherapies, such as checkpoint inhibitors or CAR-T cell therapies. Monitoring the viability and count of these cells is essential for assessing the therapeutic index of drugs that affect the hematopoietic system. Because the term encompasses a broad range of cell types and functions, it lacks the specificity required for a canonical therapeutic target name. Clinical assays often utilize flow cytometry with viability dyes like 7-AAD to quantify these cells in patient samples to ensure the quality of cell-based products or to monitor systemic toxicity.

Other names

White blood cellsLiving leukocytesLeucocytesViable WBCs

Not applicable as this is a cell population rather than a specific molecular target.